Research Grants

Our researchers actively pursue and earn awards to advance new knowledge in molecular medicine. Below is a sampling of current research grants.

Paul B. Fisher, M.Ph., Ph.D.

Developing an Effective Therapy for Metastatic Prostate Cancer, National Foundation for Cancer Research (NFCR), PI
Massey Cancer Center Core Support, P30 CA16059-30, Co-Program Leader, Molecular Cancer Genetics Program
Targeting ‘Danger’ Sensing Pattern Recognition Receptors for Prostate Cancer Therapy, DOD, W81XWH-11-1-0480, Co-PI (P.B. Fisher, X.-Y. Wang, Co-PI)
AEG-1: Novel Gene Involved in Malignant Glioma, R01 CA134721, National Institutes of Health/National Cancer Institute, PI
Mcl-1 in apoptosis and signal transduction: a structure/function approach, R01 CA168517, National Institutes of Health/National Cancer Institute, PI (Pellecchia and Fisher)
Promoter-Driven Molecular Radiotherapy for Prostate Cancer, A David Mazzone Challenge Award, Prostate Cancer Foundation, PI (Pomper, Fisher, Sgouros)
Institutional Research and Academic Career Development Award (IRACDA), National Institutes of Health, PI

PLK1-mediated Regulation of FOXO1 in Prostate Cancer, DOD, W81XWH-10-1-0204, PI

Targeting AML with PI3K/AKT inhibitors and BH3-mimetics, NIH/NCI, 4R01CA167708-04, PI
Targeting Multiple Myeloma with Smac-mimetics and HDAC inhibitors, NIH, 1R01CA205607-01, PI
SPORE in Myeloma, Project 4: Targeting Multiple Myeloma by Combining CDK Inhibitors and Bcl-2 Antagonists, NIH/NCI, P50 CA142509-04, PI – Project 4
NAE and HDAC inhibition in refractory AML and MDS, Leukemia and Lymphoma Society, **1906-14, PI
African American cancer clinical trial decisions: Testing tailored messaging, ACS,**126881-RSG-14-227-01-CD, PI
Massey Cancer Center Core Support, 5P30 CA16059, Co-Program Leader, Cancer Cell Signaling Program, Assistant Director for Translational Research
Wee1 and HDAC inhibition in relapsed/refractory AML, NIH/NCI, PI
Co-targeting B-cell Receptor Signaling Resistance Responses, D2015-15, V Foundation, PI
Synergistic in vitro interaction between the PLK1 inhibitor Bl 6727 (volasertib) and HDAC inhibitors (e.g. belinostat) in NHL and other malignant hematopoietic cells, Boehringer Ingelheim Pharmaceuticals, Inc, PI
Omacetaxine and Bortezomib in Non-Hodgkin's Lymphoma, TEVA, PI
UM1CA186644, NIH. This is a consortium agreement that allows Massey Cancer Center to participate in the Phase I trials with the University Health Network-Princess Margaret network, Co-I

Actin dynamics and regulation of intestinal epithelial barrier in intestinal inflammation, NIH R01 DK084953
Junctional exocytosis and breakdown of the intestinal barrier in inflammation, NIH/NIDDK, R01 DK083968

Chromatin remodeling complex NURF as regulator of cyclin D transcription in breast cancer cells, V Foundation, PI
Mechanisms of regulated transcription by the chromatin remodeling factor NURF, Jeffress Foundation, PI

Analysis of a Novel Regulator of Hepatocellular Carcinoma, NIH/NCI, R01 CA138540, PI
Analyzing the Role of Astrocyte Elevated Gene-1 (AEG-1) in Malignant Glioma, James S. McDonnell Foundation, PI

Host-tumor interactions and cancer relapse after radiation therapy, NCI/NIH/DHHS, 1R01CA175033-01, PI
Targeting ‘Danger’ Sensing Pattern Recognition Receptors for Prostate Cancer Therapy, DOD,
W81XWH-11-1-0481, Co-PI (P.B. Fisher, Co-PI)
Large stress proteins in biology and medicine, R01 CA154708, PI

MVNP, p62P392L and IL-6 in the Pathogenesis of PD, NIH/NIAMSD, 1RO1 AR057308, Co-Inv
Viral and Genetic Regulation of Abnormal OCL Activity in PD, NIH/NIAMSD, 1RO1 AR057310, Co-Inv
Massey Cancer Center Support Grant – Transgenic/Knockout Mouse Shared Resource, NIH/NCI, 5 P30 CA016059, Director of VCU Transgenic/Knockout Mouse Core
Massey Cancer Center Core Support, P30 CA16059, Co-Program Leader, Molecular Cancer Genetics Program
Role of TAF12 in the Increased VDR Activity in Paget's Disease of Bone, Department of Defense, PR110152, Co-Inv
Central Virginia Center on Drug Abuse Research, NIH/NIDA, P30 DA033934, Co-Director of Mouse Core